Richard N Channick MD
Critical Care Medicine
Associate Professor, Medicine-Massachusetts General Hospital, Harvard Medical School
Join to View Full Profile
10833 LeConte AveLos Angeles, CA 90095
Phone+1 310-825-5316
Fax+1 310-825-5316
Dr. Channick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Diego) Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1991
UMass Chan Medical SchoolResidency, Internal Medicine, 1984 - 1988
Lewis Katz School of Medicine at Temple UniversityClass of 1984
Certifications & Licensure
CA State Medical License 1988 - 2025
MA State Medical License 1986 - 2020
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Start of enrollment: 2009 Dec 01
- Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
- Effect of INO in Patients with Submassive and Massive PE Start of enrollment: 2025 Jun 01
Publications & Presentations
PubMed
- A prospective, multicenter, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus computer assisted vacuum thrombectomy for the treatmen...Rachel P Rosovsky, Stavros V Konstantinides, John M Moriarty, Suhail Y Dohad, Ido Weinberg
American Heart Journal. 2025-03-31 - Outcomes in Patients Receiving Treatment for Pulmonary Arterial Hypertension Associated With Repaired Congenital Heart Disease.Richard A Krasuski, Tobore Tobore, Sean Studer, Pavel Jansa, Olivier Sitbon
JACC. Advances. 2025-03-01 - Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension.Richard Channick, Sarah Medrek, Marion Delcroix, Sean Gaine, Pavel Jansa
JHLT Open. 2025-02-01
Lectures
- ACC-Talk: What are the Implications of the 6th World Symposium for the General Cardiologist?2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- What’s the Most Practical Approach to PAH Risk Stratification for the Clinician?2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
- Pulmonary and Critical Care MedicineHarvard Medical School ,Department Of Continuing Education, Cambridge, Massachusetts - 4/28/2013
Press Mentions
I'm Aware That I'm Rare: The Phaware® PodcastApril 8th, 2025- UCLA Receives $20 Million from Saul and Joyce Brandman Foundation for New Lung Health CenterMarch 6th, 2025
- New Insights and Potential Treatments for Pulmonary HypertensionAugust 21st, 2024
- Join now to see all
Grant Support
- Ut-15 + Conventional Therapy In Pulmonary HypertensionNational Center For Research Resources2000–2002
- RO 47-0203 In Exercise Capacity, Hemodynamics And QOL Of Pulmonary HypertensionNational Center For Research Resources2000–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
